# Rasonque

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/rasonque
Canonical HTML page: https://gethealthbrief.com/entity/rasonque

## Timeline

- **2026-08-26**: FDA Approval — FDA approves daraxonrasib (Rasonque) for metastatic pancreatic cancer, six months ahead of the regulatory deadline.
- **2025-06**: Breakthrough Therapy Designation — FDA grants daraxonrasib Breakthrough Therapy designation for advanced pancreatic cancer.

## Recent coverage (1 stories)

### FDA Clears Daraxonrasib; Pancreatic Cancer Survival Reaches 13.2 Months
2026-08-27 02:32:16 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

For healthcare providers and health systems, FDA approval of Rasonque introduces the first RAS-targeted oral therapy for metastatic pancreatic cancer, nearly doubling median overall survival from 6.6 to 13.2 months, with implications for treatment protocols, oncologist education, and patient access.
Full story: https://gethealthbrief.com/story/fda-daraxonrasib-pancreatic-cancer-survival-healthcare

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.